当前位置: 首页 > 期刊 > 《医学信息》 > 20203
编号:13515413
女贞子提取物治疗肝病的研究(5)
http://www.100md.com 2020年1月22日 《医学信息》 20203
     [23]Zhou RJ,Ye H,Wang F,et al.Apigenin inhibits d -galactosamine/LPS-induced liver injury through upregulation of hepatic Nrf-2 and PPARγ expressions in mice[J].Biochem Biophys Res Commun,2017,493(1):625-630.

    [24]Tsaroucha AK,Tsiaousidou A,Ouzounidis N,et al.Intraperitoneal administration of apigenin in liver ischemiareperfusion injury protective effects[J].Saudi J Gastroenterol,2016,22(6):415.

    [25]Lv Y,Gao X,Luo Y,et al.Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways[J].J Nutr Biochem,2019(71):110-121.

    [26]Hicks DF,Goossens N,Blas-García A,et al.Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells[J].Sci Rep,2017,7(1):42563.

    [27]莊让笑,潘旭旺,方红英,等.芹菜素纳米乳抗大鼠肝纤维化作用及对MMP-1,TIMP-1的影响[J].中国临床药理学与治疗学,2016,21(10):1122-1125.

    [28]Yang J,Pi C,Wang G.Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells[J].Biomedicine&Pharmacotherapy,2018(103):699-707.

    [29]胡冬梅.特女贞苷对四氯化碳致小鼠急性肝损伤的保护作用及其机制研究[D].西北大学,2017.

    收稿日期:2019-10-22;修回日期:2019-11-10

    编辑/肖婷婷, http://www.100md.com(吕雅云 龚先琼)
上一页1 2 3 4 5